A new CEO certainly wouldn't be taking a lower salary.  And RVX is in quite a pickle now.  With rising rates and falling Biotech, multiple study primary endpoint failures, a stopped COVID study, it must be very difficult to raise money.  A new CEO wouldn't have any more success at it.  Not without crushing shareholders.

As for Zenith, first thing a new CEO would do is hire investment bankers, move to the NASDAQ, and we would suffer a massive reverse split and dilution.  It would be a total diaster.  I suspect it's going to take until 2025 (minimum) for a deal? / buyout? (I hope; depending on results) but I'm very thankful DM is waiting it out.